1383005-20-6

Upstream product

• 128779-47-5 (2R)-3-(biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]propanoic acid 
• 76-05-1 trifluoroacetic acid 
• 1038924-61-6 (S)-5-biphenyl-4-ylmethylpyrrolidin-2-one 
• 1038924-65-0 (S)-5-biphenyl-4-ylmethyl-1-(2,2-dimethyl-propionyl)-pyrrolidin-2-one 
• 1038924-77-4 (S)-2-biphenyl-4-ylmethyl-5-oxopyrrolidine-1-carboxylic acid tert-butyl ester 
• 1383027-09-5 (3R,5R)-5-Biphenyl-4-ylmethyl-1-(2,2-dimethylpropionyl)-3-hydroxypyrrolidin-2-one 
• 1383026-37-6 [(R)-1-biphenyl-4-ylmethyl-2-(2,2-dimethyl-4,6-dioxo-[1,3]dioxan-5-yl)-2-oxoethyl]carbamic acid t-butyl ester 
• 1383026-52-5 C₂₂H₂₅NO₄ 
• 1383026-57-0 C₂₉H₃₁NO₄ 
• 1383026-68-3 C₂₄H₃₁NO₅ 

Downstream Products

• 1383005-25-1 (2R,4R)-4-[(5-acetyl-2H-pyrazole-3-carbonyl)amino]-5-biphenyl-4-yl-2-hydroxypentanoic acid trifluoroacetate 

Relevant academic research and scientific papers

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula XII: where Ra, Rb, R2, R7, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds described herein are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

NEPRILYSIN INHIBITORS

In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.